Literature DB >> 35438452

Reducing ExacTrac intrafraction imaging uncertainty for prostate stereotactic body radiotherapy using a pre-treatment CBCT.

Barry Jordan1, Luis Muñoz2, Christopher Colyer2.   

Abstract

This study evaluated the intrafractional auto-matching uncertainties of prostate-implanted fiducial markers when using the ExacTrac v6.5 (Brainlab, Feldkirchen, Germany) X-ray stereoscopic system. A customised phantom with 3 implanted gold seeds was initially positioned at the isocentre using a cone beam CT (CBCT) prior to intrafractional imaging. Progressive offsets were applied to the phantom in all six directions (3 translational, 3 rotational) of 0 mm, 1 mm, 2 mm, 0°, 1° and 2°. Subsequently, the ability of the ExacTrac image-matching functions to detect and correct these offsets was tested. For comparison, this procedure was repeated, but without a CBCT for pre-treatment positioning. The auto-matching uncertainties when a CBCT was introduced into the workflow were significantly reduced, and overall, the auto-matching statistics using the implanted marker (seeds) matching function was found to be more precise than the bony anatomy function in-phantom. The total standard deviations for the translational shifts using the implanted marker and bony anatomy functions respectively were 0.1 mm and 0.3 mm vertically, 0.1 mm and 0.3 mm longitudinally, and 0.1 mm and 0.4 mm laterally. The standard deviations for the rotational shifts using the implanted marker and bony anatomy matching functions respectively were 0.2° and 1.2° for the yaw (angle vert), 0.3° and 1.1° for the pitch (angle long), and 0.2° and 1.2° for the roll (angle lat) directions. The reduced uncertainties from introducing a CBCT for initial localisation resulted in decreased probability of inhibits due to false positives during treatment.
© 2022. Australasian College of Physical Scientists and Engineers in Medicine.

Entities:  

Keywords:  CBCT; ExacTrac; IGRT; Intrafraction; Prostate; SBRT

Mesh:

Year:  2022        PMID: 35438452     DOI: 10.1007/s13246-022-01121-7

Source DB:  PubMed          Journal:  Phys Eng Sci Med        ISSN: 2662-4729


  37 in total

1.  Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.

Authors:  Christopher R King; Sean Collins; Donald Fuller; Pin-Chieh Wang; Patrick Kupelian; Michael Steinberg; Alan Katz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-09       Impact factor: 7.038

2.  Fractionation and protraction for radiotherapy of prostate carcinoma.

Authors:  D J Brenner; E J Hall
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-03-15       Impact factor: 7.038

3.  A study of the effect of setup errors and organ motion on prostate cancer treatment with IMRT.

Authors:  Valeria Landoni; Bianca Saracino; Simona Marzi; Michaele Gallucci; Maria G Petrongari; Enrico Chianese; Michaela Benassi; Giuseppe Iaccarino; Antonella Soriani; Giorgio Arcangeli
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-01       Impact factor: 7.038

Review 4.  The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.

Authors:  Jack F Fowler
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

5.  A study of the effects of internal organ motion on dose escalation in conformal prostate treatments.

Authors:  Laura Happersett; Gig S Mageras; Michael J Zelefsky; Chandra M Burman; Steven A Leibel; Chen Chui; Zvi Fuks; Sarah Bull; C Clifton Ling; Gerald J Kutcher
Journal:  Radiother Oncol       Date:  2003-03       Impact factor: 6.280

6.  Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials.

Authors:  Christopher R King; Debra Freeman; Irving Kaplan; Donald Fuller; Giampaolo Bolzicco; Sean Collins; Robert Meier; Jason Wang; Patrick Kupelian; Michael Steinberg; Alan Katz
Journal:  Radiother Oncol       Date:  2013-09-20       Impact factor: 6.280

7.  Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer.

Authors:  Mark Ritter
Journal:  Semin Radiat Oncol       Date:  2008-10       Impact factor: 5.934

8.  Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.

Authors:  Amar U Kishan; Audrey Dang; Alan J Katz; Constantine A Mantz; Sean P Collins; Nima Aghdam; Fang-I Chu; Irving D Kaplan; Limor Appelbaum; Donald B Fuller; Robert M Meier; D Andrew Loblaw; Patrick Cheung; Huong T Pham; Narek Shaverdian; Naomi Jiang; Ye Yuan; Hilary Bagshaw; Nicolas Prionas; Mark K Buyyounouski; Daniel E Spratt; Patrick W Linson; Robert L Hong; Nicholas G Nickols; Michael L Steinberg; Patrick A Kupelian; Christopher R King
Journal:  JAMA Netw Open       Date:  2019-02-01

Review 9.  Hypofractionated radiotherapy for prostate cancer.

Authors:  Nina-Sophie Hegemann; Matthias Guckenberger; Claus Belka; Ute Ganswindt; Farkhad Manapov; Minglun Li
Journal:  Radiat Oncol       Date:  2014-12-06       Impact factor: 3.481

10.  Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study.

Authors:  Alan Jay Katz; Josephine Kang
Journal:  Front Oncol       Date:  2014-09-02       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.